Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

References

Page 1

	Year	Citations
Identification and characterization of a new member of the TNF family that induces apoptosis Steven R. Wiley, Ken Schooley, Pamela J. Smolak, Immunity InflammationCytokineSignaling PathwayMedicineReceptor Tyrosine Kinase	1995	2.9K
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo Henning Walczak, Robert E. Miller, K. Ariail, Nature Medicine InflammationAnti-inflammatoryMedicineApoptosisPharmacology	1999	2.5K
Safety and antitumor activity of recombinant soluble Apo2 ligand Avi Ashkenazi, Roger Pai, Sharon Fong, Journal of Clinical Investigation Apo2l MrnaMedicinal ChemistryApo2l TreatmentAntitumor ActivityMedicine	1999	2.2K
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family Robert Pitti, Scot A. Marsters, Siegfried Ruppert, Journal of Biological Chemistry	1996	1.8K
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors James P. Sheridan, Scot A. Marsters, Robert Pitti, Science Signal TransductionSignaling PathwayG Protein-coupled ReceptorMedicineReceptor Tyrosine Kinase	1997	1.7K
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice Erika Cretney, Kazuyoshi Takeda, Hideo Yagita∥, The Journal of Immunology	2002	592
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL Thomas S. Griffith, Steven R. Wiley, Marek Kubin, The Journal of Experimental Medicine ApoptosisImmunologyMonocyte-mediated Tumoricidal ActivityCell DeathPathology	1999	467
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice Salah-Eddine Lamhamedi-Cherradi, Shijun J. Zheng, Kimberly A. Maguschak, Nature Immunology Lymphocyte DevelopmentImmunodeficienciesImmunologyImmune RegulationPathology	2003	346
Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1 Anthony W. Tolcher, Monica Mita, Neal J. Meropol, Journal of Clinical Oncology	2007	311
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers Ruth Plummer, Gerhardt Attard, Simon Pacey, Clinical Cancer Research	2007	243

Page 1